ARVN - Arvinas Announces Chief Financial Officer Transition | Benzinga
- Sean Cassidy leaving Arvinas as of February 29, 2024 -
- Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer -
NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that after more than a decade with the company, Sean Cassidy, C.P.A, Chief Financial Officer and Treasurer, will be leaving the company to pursue a new opportunity, effective February 29, 2024. The Arvinas Board of Directors has launched a formal search process to identify Mr. Cassidy's permanent replacement. While this search is underway, Randy Teel, Ph.D., Arvinas' current Senior Vice President of Corporate and Business Development, will assume the role of interim Chief Financial Officer and Treasurer.
"Sean has been an integral part of Arvinas' journey since the very beginning, having served as Chief Financial Officer since 2013," said John Houston, Ph.D., Chairperson, Chief Executive Officer, and President at Arvinas. "On behalf of the leadership team, we are grateful for his dedication and leadership as CFO and the pivotal role he has played in creating Arvinas' strong financial profile and building a talented finance organization as we have pioneered our PROTAC® platform. I would also like to express my deep-felt gratitude for our friendship and wish him the best in his next endeavor."
"It has been an incredible journey contributing to the ...